Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2008-06-20
2011-12-13
Desai, Anand (Department: 1656)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C536S023100, C424S498000
Reexamination Certificate
active
08076282
ABSTRACT:
It has now been found that after administration to a diseased person or person that is at risk for developing such disease of a neutraceutical or pharmaceutical composition that comprisesa/ a lipid fraction comprising at least one of docosahexanoic acid (DHA), docosapentaenoic acid (DPA) and eicosapentaenoic acid (EPA);b/ a protein fraction comprising proteinaceous material from non-human origin which provide at least cysteine and/or taurine; andc/ a mineral fraction comprising at least one of manganese and molybdene, the health of these persons improves. Membrane function of several types of mammalian cells improves, which allows efficient treatment of immune related disorders, such as allergy, autoimmune diseases, cancer, cognitive dysfunction and other diseases of the nervous system, neuropathies, such as diabetic neuropathies and neuropathic pains, neuronal damage during insulin resistance, and gut diseases and support of the development of gut and lung function during growth or recovery.
REFERENCES:
patent: 6187761 (2001-02-01), Bijl
patent: 6339085 (2002-01-01), Haque
patent: 6391362 (2002-05-01), Gorewit
patent: 6548519 (2003-04-01), Haque
patent: 6586614 (2003-07-01), Cowan
patent: 6824809 (2004-11-01), Goudedranche et al.
patent: 2005/0009779 (2005-01-01), Kiliaan et al.
patent: 2005/0176676 (2005-08-01), Watkins et al.
patent: 2005/0203053 (2005-09-01), Wurtman et al.
patent: 2006/0280776 (2006-12-01), Koide
patent: 2008/0292724 (2008-11-01), Hageman et al.
patent: 2008/0317868 (2008-12-01), Hageman et al.
patent: 2009/0022813 (2009-01-01), Hageman
patent: 0 302 481 (1989-02-01), None
patent: 0 311 091 (1989-04-01), None
patent: 0 367 724 (1990-05-01), None
patent: 0 484 266 (1992-05-01), None
patent: 1 279 400 (2003-01-01), None
patent: 1 426 053 (2004-06-01), None
patent: 1 714 660 (2006-10-01), None
patent: WO 02/087593 (2002-11-01), None
patent: WO 2004/028529 (2004-04-01), None
patent: WO 2005/023021 (2005-03-01), None
patent: WO 2005/027663 (2005-03-01), None
patent: WO 2005/051091 (2005-06-01), None
patent: WO 2005/060954 (2005-07-01), None
Brown and London, “Structure and Function of Sphingolipid- and Cholesterol-rich Membrane Rafts,”J. Biol. Chem., 275:17221-17224 (2000).
Hashimoto et al., “Chronic Administration of Docosahexaenoic Acid Ameliorates the Impairment of Spatial Cognition Learning Ability in Amyloid β-Infused Rates,”J. Nutrition, 135(3):549-555 (2005).
Koide, Derwent Abstract No. XP-002468664, corresponding to WO 2005/023021.
Lehner and Estoppey, “Dosage de la graisse dans les farines, en particulier celles contenant du lait, d'aprés ne modification de la méthode Roese-Gottlieb” (“Proportions of fats in flour, particularly those containing milk after modification by the Roese-Gottlieb method”),Mitt. Lebensmitteluntersuchung Hyg., 45:183-185 (1954) (in French with summary in English).
Ma et al., “n-3 PUFA and membrane microdomains: a new frontier in bioactive lipid research,”J. Nutr. Biochem., 15(11):700-706 (2004).
Nettleton and Katz, “n-3 Long-Chaing Polyunsaturated Fatty Acids in Type 2 Diabetes: A Review,”J. Am. Diet. Assoc., 105(3):428-440 (2005).
Profita et al., “Muscarinic receptors, leukotriene B4produciton and neutrophilic inflammation in COPD patients,”Allergy, 60:1361-1369 (2005).
English abstract of EP 0 311 091, (1989).
Banner & Witcoff , Ltd.
Desai Anand
N.V. Nutricia
LandOfFree
Composition for improving membrane composition and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Composition for improving membrane composition and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Composition for improving membrane composition and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4260383